Business
Co-PSMA abstract accepted for oral presentation at EAU Annual Congress 2026
Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the acceptance of an abstract on the Co-PSMA (NCT06907641)[1] Investigator-Initiated Trial (IIT), led by Prof Louise Emmett at St Vincent's Hospital Sydney, for oral presentation at the upcoming European Association of Urology (EAU) Congress 2026, Europe's bigge
About this update from Clarity Pharmaceuticals Ltd.
[{"type":"text","content":"SYDNEY, Dec. 24, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the acceptance of an abstract on the Co-PSMA (NCT06907641)[1] Investigator-Initiated Trial (IIT), led by Prof Louise Emmett at St Vincent's Hospital Sydney, for oral presentation at the upcoming European Association of Urology (EAU) Congress 2026, Europe's biggest urological conference, to be held 13-16 March 2026 in London, UK[2].","length":637,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Clarity Pharmaceuticals)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Clarity Pharmaceuticals)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":98,"url":"https://media.zenfs.com/en/prnewswire.com/2ced23e8ddb3b1ec6ef537b99f6e12a7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/fkXRk3krOQ3AG6qYDObpxg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE3MztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/2ced23e8ddb3b1ec6ef537b99f6e12a7","width":400,"height":98}},"href":"https://mma.prnewswire.com/media/1700068/Clarity_Large_Logo_high_res_ID_42691c6bc5c0_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Co-PSMA's official study title is "Comparative performance of 64Copper [64Cu]-SAR-bisPSMA vs. 68Ga-PSMA-11 PET CT for the detection of prostate cancer recurrence in the setting of biochemical failure following radical prostatectomy". This Phase II IIT evaluated the performance of Clarity's diagnostic product, 64Cu-SAR-bisPSMA, in a head-to-head comparison to standard-of-care (SOC) 68Ga-PSMA-11 in 50 patients with low prostate-specific antigen (PSA) who were candidates for curative salvage therapy. Eligible patients were required to have had radical prostatectomy with no salvage therapy and a PSA level between 0.2 and 0.75 ng/mL.","length":684,"tagName":"p"},{"type":"text","content":"The results to be presented by Prof Emmett at the EAU Congress 2026 will expand on the earlier findings that the trial met its primary endpoint, demonstrating that 64Cu-SAR-bisPSMA positron emission tomography (PET) / computed tomography (CT) detec...